Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: Results of a prospective pharmacodynamic study

Journal of Cardiovascular Translational Research

Volumn 7, Issue 1, 2014, Pages 53-63

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Cho, Jung Rae ^a   Degroat, Christopher ^a   Bhatti, Mona ^a   Ferrante, Elisabetta ^a   Patel, Ronakkumar ^a   Darlington, Andrew ^a   Tello Montoliu, Antonio ^a   Desai, Bhaloo ^a   Ferreiro, Joséluis ^a   Muniz Lozano, Ana ^a   Zenni, Martin M ^a   Guzman, Luis A ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Clopidogrel; Platelets; Smoking; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; COTININE; FIBRIN; PROSTAGLANDIN E1; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PILOT STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; THROMBOCYTE AGGREGATION INHIBITION; THROMBOELASTOGRAPHY;

ADULT; AGED; ASPIRIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; COTININE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SMOKING; THROMBELASTOGRAPHY; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896738233     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9535-3     Document Type: Article

References (44)

1. Cigarette smoking among adults: United States, 2006. (2007). MMWR Morb Mortal Wkly Rep, 56, 1157-1161.
2. Ockene, I. S., & Miller, N. H. (1997). Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association: American Heart Association Task Force on Risk Reduction. Circulation, 96, 3243-3247.
3. Ambrose, J. A., & Barua, R. S. (2004). The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol, 43, 1731-1737.
4. Mangiacapra, F., & Barbato, E. (2013). Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res, 6, 310-315.
5. Zhao, Z. G., Chen, M., Peng, Y., Chai, H., Liu, W., Li, Q., Ren, X., Wang, X. Q., Luo, X. L., Zhang, C., Huang, D. J. (2013). The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart Jun 8. [Epub ahead of print].
6. Gagne, J. J., Bykov, K., Choudhry, N. K., Toomey, T. J., Connolly, J. G., & Avorn, J. (2013). Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ, 347, f5307.
7. Gurbel, P. A., Nolin, T. D., & Tantry, U. S. (2012). Clopidogrel efficacy and cigarette smoking status. JAMA, 307, 2495-2496.
8. Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., & Sabatine, M. S. (2009). Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol, 53, 1273-1278.
9. Berger, J. S., Bhatt, D. L., Steinhubl, S. R., Shao, M., Steg, P. G., Montalescot, G., Hacke, W., Fox, K. A., Lincoff, A. M., Topol, E. J., Berger, P. B., & CHARISMA Investigators. (2009). Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation, 120, 2337-2344.
10. Mehta, S. R., Tanguay, J. F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H. J., Budaj, A., Avezum, A., Widimsky, P., Steg, P. G., Bassand, J. P., Montalescot, G., Macaya, C., Di Pasquale, G., Niemela, K., Ajani, A. E., White, H. D., Chrolavicius, S., Gao, P., Fox, K. A., Yusuf, S., & CURRENT-OASIS 7 trial investigators. (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, 376, 1233-1243.
11. Saraff, K. Y., Steinhubl, S. R., Hsu, A. P., & Topol, E. J. (2006). Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention. J Am Coll Cardiol, 47, p36B [Abstract].
12. Ferreiro, J. L., Bhatt, D., Ueno, M., Bauer, D., & Angiolillo, D. J. (2013). Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013.10.043.
13. Salek, F. S. (2010). Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction. Pharmacotherapy, 30, 154e [Abstract].
14. Hochholzer, W., Trenk, D., Mega, J. L., Morath, T., Stratz, C., Valina, C. M., O'Donoghue, M. L., Bernlochner, I., Contant, C. F., Gou, J., Sabatine, M. S., Schömig, A., Neumann, F. J., Kastrati, A., Wiviott, S. D., & Sibbing, D. (2011). Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J, 162, 518-526.
15. Bliden, K. P., Dichiara, J., Lawal, L., Singla, A., Antonino, M. J., Baker, B. A., Bailey, W. L., Tantry, U. S., & Gurbel, P. A. (2008). The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol, 52, 531-533.
16. Ueno, M., Ferreiro, J. L., Desai, B., Tomasello, S. D., Tello-Montoliu, A., Capodanno, D., Capranzano, P., Kodali, M., Dharmashanker, K., Charlton, R. K., Bass, T. A., & Angiolillo, D. J. (2012). Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv, 5, 293-300.
17. Gurbel, P. A., Bliden, K. P., Logan, D. K., Kereiakes, D. J., Lasseter, K. C., White, A., Angiolillo, D. J., Nolin, T. D., Maa, J. F., Bailey, W. L., Jakubowski, J. A., Ojeh, C. K., Jeong, Y. H., Tantry, U. S., & Baker, B. A. (2013). The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol, 62, 505-512.
18. Gremmel, T., Steiner, S., Seidinger, D., Koppensteiner, R., Panzer, S., & Kopp, C. W. (2009). Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res, 124, 588-591.
19. Faber, M. S., & Fuhr, U. (2004). Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther, 76, 178-184.
20. Washio, I., Maeda, M., Sugiura, C., Shiga, R., Yoshida, M., Nonen, S., Fujio, Y., & Azuma, J. (2011). Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos, 39, 1-3.
21. CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329-1339.
22. Shanker, G., Kontos, J. L., Eckman, D. M., Wesley-Farrington, D., & Sane, D. C. (2006). Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis, 22, 213-220.
23. Wall, M. A., Johnson, J., Jacob, P., & Benowitz, N. L. (1988). Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health, 78, 699-701.
24. Ueno, M., Ferreiro, J. L., Tomasello, S. D., Tello-Montoliu, A., Capodanno, D., Seecheran, N., Kodali, M., Dharmashankar, K., Desai, B., Charlton, R. K., Bass, T. A., & Angiolillo, D. J. (2011). Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv, 4, 905-912.
25. Tello-Montoliu, A., Thano, E., Rollini, F., Patel, R., Wilson, R. E., Muñiz-Lozano, A., Franchi, F., Darlington, A., Desai, B., Guzman, L. A., Bass, T. A., & Angiolillo, D. J. (2013). Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Thromb Haemost, 110, 777-784.
26. Gurbel, P. A., Bliden, K. P., Guyer, K., Aggarwal, N., & Tantry, U. S. (2007). Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res, 119, 563-570.
27. Barua, R. S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., Margosan, D., & Ambrose, J. A. (2010). Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol, 30, 75-79.
28. Angiolillo, D. J., Capranzano, P., Desai, B., Shoemaker, S. B., Charlton, R., Zenni, M. M., Guzman, L. A., & Bass, T. A. (2009). Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res, 124, 318-322.
29. Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004). Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract, 10, 307-312.
30. Prodan, C. I., Joseph, P. M., Vincent, A. S., & Dale, G. L. (2007). Coated-platelet levels are influenced by smoking, aspirin, and selective serotonin reuptake inhibitors. J Thromb Haemost, 5, 2149-2151.
31. Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007). Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 298, 2654-2664.
32. Smith, S. C., Jr., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Lloyd-Jones, D. M., Minissian, M., Mosca, L., Peterson, E. D., Sacco, R. L., Spertus, J., Stein, J. H., & Taubert, K. A. (2011). AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol, 58, 2432-2446.
33. Tantcheva-Poór, I., Zaigler, M., Rietbrock, S., & Fuhr, U. (1999). Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasian using saliva-based caffeine test. Pharmacogenetics, 9, 131-144.
34. Park, K. W., Kang, S. H., Kang, J., Jeon, K. H., Park, J. J., Han, J. K., Koh, J. S., Lee, S. E., Yang, H. M., Lee, H. Y., Kang, H. J., Koo, B. K., Oh, B. H., Park, Y. B., & Kim, H. S. (2012). Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. Heart, 98, 1000-1006.
35. Wennmalm, A., Benthin, G., Granström, E. F., Persson, L., Petersson, A. S., & Winell, S. (1991). Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation, 83, 1698-1704.
36. Pamukcu, B., Oflaz, H., Onur, I., Cimen, A., & Nisanci, Y. (2011). Effects of cigarette smoking on platelet aggregation. Clin Appl Thromb Hemost, 17, E175-E180.
37. Loke, W. M., Lam Mok Sing K., Lee, C. Y., Chong, W. L., Chew, S. E., Huang, H., Looi, W. F., Quek, A. M., Lim, E. C., Seet, R. C. (2012). Cyclooxygenase-1-mediated platelet reactivity in young male smokers. Clin Appl Thromb Hemost Dec 14. [Epub ahead of print]
38. Henry, P., Vermillet, A., Boval, B., Guyetand, C., Petroni, T., Dillinger, J. G., Sideris, G., Sollier, C. B., & Drouet, L. (2011). 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost, 105, 336-344.
39. Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K. H., Easton, J. D., Hamm, C., Hu, T., Fox, K. A., & Topol, E. J. (2008). Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization. Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation, 118, 1705-1712.
40. Angiolillo, D. J., Ueno, M., & Goto, S. (2010). Basic principles of platelet biology and clinical implications. Circ J, 74, 597-607.
41. Cimmino, G., & Golino, P. (2013). Platelet biology and receptor pathways. J Cardiovasc Transl Res, 6, 299-309.
42. Monroe, D. M., Hoffman, M., & Roberts, H. R. (2002). Platelets and thrombin generation. Arterioscler Thromb Vasc Biol, 22, 1381-1389.
43. Leon, C., Ravanat, C., Freund, M., Cazenave, J. P., & Gachet, C. (2003). Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol, 23, 1941-1947.
44. Norgard, N. B., Saya, S., Hann, C. L., Hennebry, T. A., Schechter, E., & Dale, G. L. (2008). Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. J Cardiovasc Pharmacol, 52, 536-539.